Skip to main content

Table 2 Clinical evidence for adoptive transfer of EBV-specific T cells

From: Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation

Reference Method No. of patients Results Dose
In vitro stimulation and expansion
Rooney et al. (1995) [25] Allogeneic EBV-specific CD8+ T cells 10 Therapy: 3/3 responders Prophylaxis: 7/7 virus free 0.2–1.2 × 108 cells/m2
Rooney et al. (1998) [26] Allogeneic EBV-specific CD8+ T cells 39 Prophylaxis: all PTLD free 0.2–1.0 × 108 cells/m2
Haque et al. (2002) [50] Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II 8 4/8 remission 106 cells/kg
Haque et al. (2007) [51] Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase II 33 14/33 complete remission 3/33 partial response 2 × 106 cells/kg
Heslop et al. (2010) [49] Allogeneic EBV-specific CD8+ T cells 114 Therapy: 11/13 complete response prophylaxis: all PTLD free 1–5 × 107 cells/m2
Doubrovina et al. (2012) [63] Allogeneic EBV-specific CD8+ T cells 19 13/19 complete response 106 cells/kg
Gallot et al. (2014) [64] Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II 11 4/10 responders 5 × 106 cells/kg
Withers et al. (2017 and 2018) [55, 59] EBV-specific third-party CD8+ and CD4+ T cells phase I 1 0/1 responded 1 infusion of 1.37–5.0 × 107 cells/m2
Direct isolation via peptide-HLA multimers
Uhlin et al. (2010) [65] Allogeneic EBV-specific CD8+ T cells using MHC-I-pentamers 1 1/1 complete response 1.1 × 104 cells/kg and 2 × 104 cells/kg
Direct isolation via cytokine-capture technique
Moosmann et al. (2010) [66] EBV-specific polyclonal CD8+ and CD4+ T cells 6 3/6 responders 0.4–9.7 × 104 cells/kg
Icheva et al. (2013) [29] EBV-specific polyclonal CD8+ and CD4+ T cells 10 7/10 responders 0.15–53.8 × 103 cells/kg
Kàllay et al. (2018) [43] EBV-specific polyclonal CD8+ and CD4+ T cells 2 2/2 responders 1.8–2.3 × 104 cells/kg